TruLaw partners with pharmaceutical litigation leaders whose track records include substantial settlements and verdicts in pharmaceutical failure-to-warn cases, providing clients with representation from attorneys whom judges and defense counsel take seriously
A healthcare provider will usually review: Health history Body weight Kidney function Cardiovascular risk factors Existing medications Personal or family history of certain conditions This helps determine whether GLP-1 treatment is safe, appropriate, and clinically indicated for eligible individuals
[9] This conservative approach is meant to protect the infant from any exposure that might cause hemolytic anemia or other adverse effects, as infants, especially neonates, have immature metabolic pathways and could be more susceptible to MBs toxicities (similar to how newborns are sensitive to certain antibiotics or dyes)
Even Phe could be considered as a potential replacement, and Lys from exenatide/CY-5 also seems feasible
doi: 10.1056/NEJMoa2416394 30